AU2018244806B2 - An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer - Google Patents

An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer Download PDF

Info

Publication number
AU2018244806B2
AU2018244806B2 AU2018244806A AU2018244806A AU2018244806B2 AU 2018244806 B2 AU2018244806 B2 AU 2018244806B2 AU 2018244806 A AU2018244806 A AU 2018244806A AU 2018244806 A AU2018244806 A AU 2018244806A AU 2018244806 B2 AU2018244806 B2 AU 2018244806B2
Authority
AU
Australia
Prior art keywords
agent
bad
cancer
expression
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018244806A
Other languages
English (en)
Other versions
AU2018244806A1 (en
Inventor
Angus Dalgleish
Wai LUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LDN Pharma Ltd
Original Assignee
LDN Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1704910.7A external-priority patent/GB201704910D0/en
Priority claimed from GBGB1718806.1A external-priority patent/GB201718806D0/en
Application filed by LDN Pharma Ltd filed Critical LDN Pharma Ltd
Publication of AU2018244806A1 publication Critical patent/AU2018244806A1/en
Application granted granted Critical
Publication of AU2018244806B2 publication Critical patent/AU2018244806B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018244806A 2017-03-28 2018-03-28 An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer Active AU2018244806B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1704910.7A GB201704910D0 (en) 2017-03-28 2017-03-28 High dose combi I
GB1704910.7 2017-03-28
GB1718806.1 2017-11-14
GBGB1718806.1A GB201718806D0 (en) 2017-11-14 2017-11-14 Breast cancer treatment
PCT/GB2018/050843 WO2018178690A1 (en) 2017-03-28 2018-03-28 An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2018244806A1 AU2018244806A1 (en) 2019-11-21
AU2018244806B2 true AU2018244806B2 (en) 2023-12-21

Family

ID=61952738

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018244806A Active AU2018244806B2 (en) 2017-03-28 2018-03-28 An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer

Country Status (9)

Country Link
US (1) US20200101066A1 (enExample)
EP (1) EP3600433B1 (enExample)
JP (2) JP7657590B2 (enExample)
KR (2) KR20200072445A (enExample)
CN (1) CN111050801B (enExample)
AU (1) AU2018244806B2 (enExample)
CA (1) CA3083850A1 (enExample)
ES (1) ES2897790T3 (enExample)
WO (1) WO2018178690A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139352A1 (en) * 2001-10-30 2003-07-24 Schoenhard Grant L. Inhibitors of ABC drug transporters in cancer cells
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
US20160106832A1 (en) * 2013-05-10 2016-04-21 Cancer Vaccine Institute Treatment of cancer with naltrexone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE326222T1 (de) 2000-03-15 2006-06-15 Wolfgang Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
AU2006275914A1 (en) * 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
JP6008866B2 (ja) * 2010-12-03 2016-10-19 オレキシジェン・セラピューティクス・インコーポレーテッド ナルトレキソン療法における薬物バイオアベイラビリティの増加
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139352A1 (en) * 2001-10-30 2003-07-24 Schoenhard Grant L. Inhibitors of ABC drug transporters in cancer cells
US20160106832A1 (en) * 2013-05-10 2016-04-21 Cancer Vaccine Institute Treatment of cancer with naltrexone
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression

Also Published As

Publication number Publication date
KR20240125082A (ko) 2024-08-19
ES2897790T3 (es) 2022-03-02
CN111050801A (zh) 2020-04-21
JP2020515649A (ja) 2020-05-28
CA3083850A1 (en) 2019-10-04
JP7657590B2 (ja) 2025-04-07
EP3600433A1 (en) 2020-02-05
AU2018244806A1 (en) 2019-11-21
KR20200072445A (ko) 2020-06-22
EP3600433B1 (en) 2021-05-05
WO2018178690A1 (en) 2018-10-04
CN111050801B (zh) 2023-03-28
JP2025027084A (ja) 2025-02-26
US20200101066A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
US11351165B2 (en) Agent that increases the expression of the opioid kappa 1 for the treatment of cancer
US10959984B2 (en) Methods for treating cancer with RORγ inhibitors
JP7564119B2 (ja) ナルトレキソン及びカンナビノイドを含む癌の治療
Li et al. A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma
TW201609094A (zh) 治療癌症之新穎方法
TW201722422A (zh) 用於治療癌症之合理組合療法
AU2018244806B2 (en) An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer
JP7282072B2 (ja) 肺がんの治療に使用するための組み合わせ
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
Gömeç et al. Investigation of the potential antitumor activity of PLK1 inhibitor SBE13 in colon cancer cell line HT29
Narayanan Anticancer Effect of Indanone-Based Thiazolyl Hydrazone Derivative on P53 Mutant Colon Cancer Cell Lines: In Vitro and in Vivo Study
Pacey et al. 382 Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study
HK1229695A1 (en) Novel methods for treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)